RNA · Avidity Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · RNA
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $12.47M | $3.85M | $1.57M | - | $2.34M | $2.04M | $3.54M | - | $2.82M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $154.95M | $138.13M | $99.49M | - | $77.20M | $63.94M | $66.83M | - | $47.71M |
| SG&A | - | $46.33M | $36.86M | $33.60M | - | $23.27M | $20.73M | $13.90M | - | $13.73M |
| Total Operating Expenses | - | $201.28M | $174.99M | $133.09M | - | $100.47M | $84.67M | $80.73M | - | $61.44M |
| D&A | - | $1.10M | $800.0K | $785.0K | - | $700.0K | $700.0K | $641.0K | - | $600.0K |
| Operating Income | - | ($188.81M) | ($171.14M) | ($131.52M) | - | ($98.13M) | ($82.63M) | ($77.19M) | - | ($58.63M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($174.44M) | ($157.31M) | ($115.77M) | - | ($80.40M) | ($70.79M) | ($68.86M) | - | ($52.36M) |
| EPS - Basic | - | ($1.27) | ($1.21) | ($0.90) | - | ($0.65) | ($0.65) | ($0.79) | - | ($0.71) |
| EPS - Diluted | - | ($1.27) | ($1.21) | ($0.90) | - | ($0.65) | ($0.65) | ($0.79) | - | ($0.71) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $382.52M | $350.16M | $243.91M | $254.20M | $219.87M | $370.19M | $575.75M | $471.40M | $185.08M | $85.65M |
| Accounts Receivable | - | - | - | - | $0 | $0 | $0 | $1.57M | $1.10M | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $12.40M | $9.63M | $3.91M | $6.63M | $8.46M | $7.66M | $8.89M | $2.35M | $8.81M | $5.55M |
| Current Assets | $1.80B | $1.97B | $1.25B | $1.43B | $1.54B | $1.62B | $1.33B | $934.47M | $611.31M | $555.49M |
| Total Assets | $1.96B | $2.13B | $1.37B | $1.46B | $1.56B | $1.64B | $1.35B | $951.47M | $628.55M | $573.16M |
| Current Liabilities | $195.45M | $169.88M | $135.06M | $84.86M | $98.02M | $91.33M | $84.21M | $74.95M | $80.68M | $48.72M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $269.45M | $247.94M | $176.26M | $130.35M | $138.94M | $137.39M | $126.39M | $120.58M | $127.79M | $55.70M |
| Stockholders' Equity | $1.69B | $1.89B | $1.19B | $1.33B | $1.42B | $1.50B | $1.22B | $830.90M | $500.76M | $517.47M |
| Retained Earnings | ($1.58B) | ($1.34B) | ($1.17B) | ($1.01B) | ($893.07M) | ($790.81M) | ($710.41M) | ($639.62M) | ($570.76M) | ($510.32M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($124.83M) | - | - | - | ($70.38M) | - | - |
| Investing Cash Flow | - | - | - | $157.19M | - | - | - | ($32.75M) | - | - |
| Financing Cash Flow | - | - | - | $1.94M | - | - | - | $389.44M | - | - |
| CapEx | - | - | - | $3.75M | - | - | - | $915.0K | - | - |
| Free Cash Flow | - | - | - | ($128.58M) | - | - | - | ($71.30M) | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -1513.5% | -4448.7% | -8360.9% | - | -4200.9% | -4040.4% | -2178.6% | - | -2080.4% |
| EBITDA margin | - | -1504.7% | -4427.9% | -8311.0% | - | -4171.0% | -4006.2% | -2160.5% | - | -2059.1% |
| Net margin | - | -1398.3% | -4089.3% | -7360.0% | - | -3441.7% | -3461.8% | -1943.4% | - | -1858.0% |
| Free cash flow margin | - | - | - | -8174.3% | - | - | - | -2012.3% | - | - |
| FCF / Net income | - | - | - | 1.11 | - | - | - | 1.04 | - | - |
| R&D / Revenue | - | 1242.1% | 3590.5% | 6324.9% | - | 3304.7% | 3126.7% | 1886.3% | - | 1693.2% |
| SG&A / Revenue | - | 371.4% | 958.3% | 2136.0% | - | 996.3% | 1013.7% | 392.3% | - | 487.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -8.2% | -11.5% | -7.9% | - | -4.9% | -5.3% | -7.2% | - | -9.1% |
| Return on equity | - | -9.2% | -13.2% | -8.7% | - | -5.3% | -5.8% | -8.3% | - | -10.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.20 | 11.57 | 9.26 | 16.91 | 15.73 | 17.76 | 15.78 | 12.47 | 7.58 | 11.40 |
| Quick ratio | 9.20 | 11.57 | 9.26 | 16.91 | 15.73 | 17.76 | 15.78 | 12.47 | 7.58 | 11.40 |
| Cash ratio | 1.96 | 2.06 | 1.81 | 3.00 | 2.24 | 4.05 | 6.84 | 6.29 | 2.29 | 1.76 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.16 | 1.13 | 1.15 | 1.10 | 1.10 | 1.09 | 1.10 | 1.15 | 1.26 | 1.11 |
| Liabilities / Assets | 0.14 | 0.12 | 0.13 | 0.09 | 0.09 | 0.08 | 0.09 | 0.13 | 0.20 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.01 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | 0d | 0d | 162d | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 434.0% | 88.1% | -55.6% | - | -17.1% | -11.7% | 58.7% | - | 13.5% |
| Revenue CAGR (3y) | - | 71.3% | 20.9% | -4.3% | - | 2.6% | -7.8% | 9.4% | - | 63.1% |
| Revenue CAGR (5y) | - | 80.6% | 20.1% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -92.4% | -107.1% | -70.4% | - | -67.4% | -57.0% | -34.0% | - | -30.5% |
| Net income growth (YoY) | - | -117.0% | -122.2% | -68.1% | - | -53.6% | -50.5% | -31.4% | - | -20.1% |
| EPS growth (YoY) | - | -95.4% | -86.2% | -13.9% | - | 8.5% | 1.5% | -11.3% | - | -4.4% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -80.4% | - | - | - | -40.4% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 18.5% | 25.5% | -2.3% | 59.9% | 184.6% | 190.5% | 118.4% | 48.7% | -13.4% | 37.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$18.75M totalReportable Segment$18.75M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Avidity Biosciences against the 5 most active filers in the same SIC group.